MetLife Investment Management LLC Grows Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

MetLife Investment Management LLC raised its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 8.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 57,749 shares of the biotechnology company's stock after purchasing an additional 4,422 shares during the period. MetLife Investment Management LLC owned about 0.06% of Sarepta Therapeutics worth $7,022,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Capital International Investors lifted its stake in shares of Sarepta Therapeutics by 38.9% during the 4th quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company's stock worth $1,057,482,000 after purchasing an additional 2,437,855 shares during the last quarter. Norges Bank bought a new stake in shares of Sarepta Therapeutics in the 4th quarter valued at about $126,315,000. Brandywine Global Investment Management LLC purchased a new position in shares of Sarepta Therapeutics in the 4th quarter worth approximately $22,613,000. Swedbank AB bought a new position in shares of Sarepta Therapeutics during the 4th quarter worth approximately $16,706,000. Finally, Vanguard Group Inc. lifted its position in Sarepta Therapeutics by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 9,085,456 shares of the biotechnology company's stock valued at $1,104,701,000 after acquiring an additional 117,904 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors.

Insider Transactions at Sarepta Therapeutics

In related news, Director Claude Nicaise sold 2,491 shares of the firm's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the transaction, the director now directly owns 27,812 shares in the company, valued at $2,771,187.68. This trade represents a 8.22 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 7.70% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on SRPT shares. Needham & Company LLC reduced their price target on Sarepta Therapeutics from $202.00 to $183.00 and set a "buy" rating on the stock in a research report on Thursday, April 3rd. Scotiabank decreased their price target on Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating for the company in a research note on Thursday, March 20th. HC Wainwright restated a "neutral" rating and set a $75.00 price target on shares of Sarepta Therapeutics in a research note on Wednesday, April 16th. Royal Bank of Canada lowered shares of Sarepta Therapeutics from an "outperform" rating to a "sector perform" rating and decreased their price objective for the company from $161.00 to $87.00 in a research report on Monday, March 31st. Finally, Deutsche Bank Aktiengesellschaft dropped their target price on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating on the stock in a research report on Wednesday, March 19th. Six investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $158.70.

Sarepta Therapeutics Trading Up 0.5 %

Shares of Sarepta Therapeutics stock traded up $0.30 during trading hours on Monday, hitting $60.74. The company's stock had a trading volume of 256,076 shares, compared to its average volume of 1,420,573. The firm has a fifty day moving average of $77.32 and a 200-day moving average of $105.59. Sarepta Therapeutics, Inc. has a twelve month low of $48.01 and a twelve month high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The stock has a market cap of $5.89 billion, a price-to-earnings ratio of 48.59 and a beta of 0.93.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.